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Background: Bone-targeted agents such as bisphosphonates and the RANKL antibody have revolutio-
nised the care of patients with bone metastases. There has, however been increasing concern about the
oral health of these patients and in particular osteonecrosis of the jaw (ONJ), especially with the
increasing use of these agents at higher potencies for greater periods of time.
Methods: A review of the published data in PubMed and meeting abstracts was performed to examine
incidence, risk factors, pathogenesis, clinical course and management of osteonecrosis of the jaw with
focus on cancer patients treated with bone-targeted agents (BTA) for bone metastases. This manuscript
takes the most frequent and pertinent questions raised by oncologists, dentists and oral and
maxillofacial surgeons and tries to give a pragmatic overview of the literature.
Results: The incidence of ONJ varies depending on types of bone-targeted agents, duration of
treatment and additional risk factors. The causes and pathogenesis of ONJ is not fully elucidated,
however bone-targeted therapy induced impaired bone remodelling, microtrauma secondary to jaw
activity, and oral bacterial infection seem to be important factors. Since the treatment options for
ONJ are limited and not well established, preventive strategies have to be included in patients
management.
Conclusions: Many unanswered questions remain about the optimal oral care of patients receiving
bone-targeted agents. Prospective data collection will remedy this and help to provide practical
guidelines for the management and treatment of those patients that require dental intervention.
& 2013 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
Few drugs have revolutionised the care of metastatic cancer
patients as much as the bisphosphonates. These inhibitors of
osteoclast function have undergone extensive clinical develop-
ment over the last 20 years and have been shown to reduce
hypercalcemia, bone pain, fractures, radiotherapy use, spinal cord
compression and bone surgery in patients with bone metastases
from a range of malignancies. They have also been shown to
improve patient quality of life [1]. In addition, oncology patients
will frequently receive bisphosphonates for osteoporosis, cancer
treatment related bone loss and sometimes as an adjuvant
therapy [2]. From an oncologist’s standpoint these therapeutic. This is an open access article un
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s).beneﬁts have been achieved with very few side effects when
compared with most other systemic agents used in clinical
practice. However, what has become evident is that as these
increasingly potent bone-targeted agents are used for longer
durations of time, less common side effects such as osteone-
crosis of the jaw (ONJ) are presenting challenges not only to
oncologists but also to the dental professionals who care for
these patients.
This is becoming an increasingly important issue as the use of
new agents such as the antibody to Receptor activator of nuclear
factor kappa-B ligand (RANKL), denosumab, is also associated
with this complication. Given that there is increasing awareness
of this complication by oncologists, dental professionals and
patients alike, we felt it was timely to offer a practical guide to
assist all of us in the care of these patients. This article should
not be viewed as a comprehensive review of the literature but
more as a practical guide to assimilate the most up to date
information.der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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osteonecrosis of the jaw
2.1. What is osteonecrosis of the jaw and what other oral conditions
can it look like?
While ONJ is also called bisphosphonate-related osteonecrosis of
the jaw (BRONJ), in this article we will keep to the term ONJ as
clearly BRONJ is a misnomer considering the condition is now
described to also result from the use of non-bisphosphonate bone-
targeted agents. Some are now calling this condition chemically-
mediated ONJ, or chemo-necrosis of the jaw [3,4]. The American
Association of Oral and Maxillofacial Surgeons deﬁnes BRONJ as
‘‘exposed bone in the maxillofacial region that has persisted for
more than 8 weeks, together with current or previous treatment
with a bisphosphonate and without a history of radiation therapy to
the jaw’’ [5]. This is a relatively rare clinical entity which was ﬁrst
described ﬁrst in 2003 in cancer patients treated with potent
bisphosphonates, following by increasing evidence on incidence,
clinical pictures, staging, prophylaxis and treatment options [6].
ONJ can produce signiﬁcant morbidity in affected patients, decreas-
ing quality of life due to its chronic nature and relatively low
recovery rate [7]. Approximately 30% of patients present with
exposed bone and pain, and an additional 50% suffer from pain,
gingival swelling and purulent discharge. In severe cases (about
20%), some patients can progress to pathologic fracture of the jaw,
ﬁstula formation, severe extended bone necrosis and an infection
process in the soft tissues [8,9]. Occasionally, pain in the jaw bone
or tooth loosening may be the only symptom with no evidence of
other clinical or radiological abnormalities [10].
The diagnosis is made by a combination of clinical suspicion,
clinical examination and radiological assessment. Clinical suspi-
cion is going to be raised in those patients known to have been
receiving treatment with highly potent bone-targeted agents.
Clinical examination may reveal exposed jawbone, mucosal
swelling, erythema, ulceration and tooth mobility as well as
purulent discharge, intra- or extra-oral ﬁstula and necrotic boneFig. 1. Stages of ONJ (adapted from Bagan et al. [78]) (with permission)): (a) an initial sta
stage 1. The patient had no symptoms. (c) Osteonecrosis of the jaw; stage 2. A more ex
The patient had an extraoral (cutaneous) ﬁstula.in the more advanced cases (Fig. 1). Panoramic and cross-
sectional imaging will help determine the extent of necrosis and
the presence of a sequestrum or osteomyelitis. Involvement of the
mandible is more common than the maxilla, probably due to its
more limited blood supply, and has been estimated as being
involved in up to 70% of cases [11]. Radiology also helps to
exclude other possible aetiologies such as unerupted teeth, bony
cysts, sinusitis, temporo-mandibular joint (TMJ) pathology or
metastatic disease [12,13] (Table 1).
2.2. Causes and pathogenesis of osteonecrosis of the jaw
The mechanism for the development of ONJ is not fully under-
stood, however, several hypotheses exist. The aetiology appears to
be multi-factorial and includes bisphosphonate induced changes,
patient related factors and dental surgical procedures.
Mandibular and maxillary bones, particularly the alveolar
bone and periodontum, characterize by a high turnover rate
throughout life as response to constant mechanical stress, tooth
mobilisation, extraction or periodontal infections [14,15].
Bone healing process requires involvement of multiple cytokines
and growth factors including platelet-derived growth factors, bone
morphogenic proteins, members of the transforming growth factor
b superfamily, and members of the insulin-like growth factor family
[16]. Human gingival ﬁbroblast (HGF) and human periodontal
ligament (HPDL) cells that present in periodontal tissue express
RANKL and osteoprotegerin and provide balanced bone remodeling
[17]. Bisphosphonate have a high afﬁnity to bone tissue especially
at high remodelling sites. Bone-targeted agents clearly interfere
with bone remodelling through the osteoclast apoptosis [18,19].
This results in accumulation of died bone tissue that cannot provide
sufﬁcient blood supply to overlying mucosa and lead to bone
exposure. In addition, anti-angiogenic properties of bisphospho-
nates could contribute to vascular impairment [20,21]. Mawardi
et al. showed on the mouse bisphosphonate treated model that
bacterial infection at the tooth extraction sites causes diminished
keratinocyte-growth factor expression in gingival ﬁbroblasts andge of osteonecrosis without visible necrotic bone. (b) Osteonecrosis of the upper jaw;
tensive area of necrosis and with symptoms. (d) Osteonecrosis of the jaw; stage 3.
Table 1
Deﬁnition, diagnosis, risk factors of ONJ.
Question Answer References
What is ONJ? Exposed bone in the maxillofacial region that has persisted for more than 8 weeks, together with current or previous treatment
with a bisphosphonate, without a history of radiation therapy to the jaws
[5]
What causes ONJ? Bisphosphonate related factors: Impaired bone remodelling and [18,19,77], inhibition angiogenesis [20,21]
Patient related factors: Constant microtrauma due to jaw movement[14], Bone trauma due to surgical dental procedures [15],
Oral microﬂora may inhibit healing process and super infect poorly healing wound [22–24]
Who gets ONJ? Two main factors contribute to development of ONJ: Bone-targeted agent treatment and surgical procedures involving jaw bones [28–30,35–37]
Predisposing factors: Immunosuppressive status, increased patient’s age, local oral inﬂammatory process, chronic
corticosteroids use, concurrent chemotherapy, smoking
How do you
diagnose ONJ?
Symptoms: pain, gingival swelling, purulent discharge, exposed, non-healing bone [11]
Diagnostic procedure: Thorough dental examination, panoramic and cross-sectional imaging to determine the extent of
necrosis and the presence of a sequestrum or osteomyelitis and to exclude other possible aetiologies for these manifestations.
Differential
diagnosis of ONJ
Periodontal disease [12,13]
Gingivitis
Mucositis
Infectious osteomyelitis
Sinusitis
Periapical pathology caused by a carious infection
Temporomandibular joint disease
Osteoradionecrosis
Neuralgia-inducing cavitational osteonecrosis (NICO)
Bone tumors or metastases
Table 2
Incidence of osteonecrosis of the jaw [7,16–20].
General population Metastatic breast,
prostate cancer
Multiple
myeloma
Oral bisphosphonates 0.00038–0.06% Single reports Single reports
Pamidronate n/a 0.5–1% 1–4%
Zoledronic acid 0.06% 1.2–2.9% 1–10%
Denosumab 0% in 3 years 2% 1.1%
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tion of oral microﬂora on exposed bone surface and surrounded
mucosa might result in development of chronic infection and
further impairment of wound healing [23,24] (Table 1).
2.3. Incidence, prevalence and risk factors for osteonecrosis of the
jaw
Oral or intravenous bisphosphonates use was found to be the
most important risk factor for ONJ [25,26].
Given the heterogeneous nature of the patient population
treated by bone-targeted agents, there is considerable variability
in the choice of agents, their dose, duration of therapy and
schedule, and hence variability in the incidence and prevalence
of ONJ. In general however, patients with metastatic bone disease
receive considerably more treatment than patients treated for
osteoporosis or cancer-treatment related bone loss and therefore
it is the advanced cancer population that is more extensively
studied. In addition, given the high incidence of bone involvement
in metastatic breast, prostate cancers and multiple myeloma
patients, together with the frequent use of bone-targeted agents
in these patients for many years, it is not surprising that these are
the patients at greatest risk for ONJ [27].
While the reported incidence of ONJ varies considerably, it
tends to range between 1% and 12% based on results from
particular case series, case-controlled and cohort studies [10]
(Table 2). There is also variability in incidence across disease sites,
with rates of approximately 0–6% in patients with prostate
cancer, 1.2–2.9% in breast cancer patients and 2.4–9.9% inmultiple myeloma patients. In other malignancies the incidence
appears to be about 0–4% [28,29]. It is this variability in incidence
between cancer types that provides the greatest clues to risk
factors for ONJ. These patients all receive high cumulative
doses of potent bone-targeted agents for prolonged periods of
time. The importance of potency of the bisphosphonate is
reﬂected through the reported incidence with zoledronic acid
(incidence of ONJ of 20% after 3 years of treatment), compared
with pamidronate (7% after 4 years treatment), and oral bispho-
sphonates (0.00038–0.06%) [28–32]. The duration of bisphospho-
nate exposure is also important with cumulative rates of ONJ of
1% after 12 months of therapy rising to 11% after 4 years of
therapy [28].
As mentioned, ONJ is not just a result of bisphosphonate use.
Denosumab use has also been associated with cases of ONJ.
A recently published meta-analysis of 3 randomised trials com-
pared the efﬁcacy and safety of denosumab versus zoledronic acid
in 5723 patients with metastatic breast cancer, prostate cancer or
multiple myeloma, and prospectively evaluated the incidence of
ONJ. Similar incidences of ONJ were observed with both treat-
ments, with an incidence of 1.3% with zoledronic acid and 1.8%
with denosumab. Interestingly the median time of drug exposure
before ONJ was the same (14 months) in both groups [33].
However, it is important to realise that patients with any pre-
existing dental problem were excluded from participating in the
studies included in the meta-analysis and all patients received
regular oral examinations. It is therefore likely, given the highly
motivated nature of both the patients and the investigators in the
trials, that the real world non-trial risks of ONJ would likely be
higher.
While spontaneous cases of ONJ are reported, most (up to 80%)
are related to recent dento-alveolar trauma, including tooth
extractions, dental implant placement, periapical surgery and
periodontal procedures involving osseous injury [9,34].
The incidence of ONJ appears to increase for patients when they
have additionally undergone an invasive dental procedure, and are
approximately 9–50% in patients on intravenous bisphosphonate
and 1–8% in patients receiving oral bisphosphonates. These proce-
dures thus appear to result in an increase in the risk of developing
ONJ by 5–21-fold [35]. It is important however to note that
periodontal disease and bone exostosis (which in themselves
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signiﬁcant independent risk factors for ONJ [28]. Other predisposing
factors include: chronic steroid use in conjunction with bispho-
sphonates, particularly in the management of patients with multi-
ple myeloma; and an immuno-compromised state secondary to
concomitant chemotherapeutic agents and diabetes [25,36–38].
There is a controversy for role of anti-angiogenic therapy on
development of ONJ. Some reports support signiﬁcant increase in
ONJ incidence in patients treated with anti-angiogenic agents
[39,40]. Moreover, patients receiving anti-angiogenic agents
including bevacizumab and sunitinib have doubled the risk of
ONJ compared to patients who have not been exposed to such
treatment following meta-analysis of denosumab trials [33]. On
the other hand analysis of three large prospective trials of
bevacizumab in metastatic breast cancer revealed 0.9–2.4% risk
of ONJ in patients receiving concomitant bisphosphonates and
bevacizumab, which was comparable with those receiving
bisphosphonates alone [41]. In general, however, what is clear
is that the more risk factors a patient has, the greater the risk of
developing ONJ, which can reach 10–20% in patients with more
than one risk factor [42].
A systematic review by Migliorati et al. showed variable
prevalence of ONJ depending on study type, duration of follow
up and type of bisphosphonate. While in studies with documen-
ted follow up prevalence was as high as 13.3%, in studies only
0.7%. Analysis of epidemiological studies resulted in prevalence
1.2%. As for type of bisphosphonate the overall prevalence for
patients using zoledronic acid was 8.6%, for pamidronate 7.3%,
and 21% for both. Prevalence was much higher in cancer patients
(89%), and patients with multiple myeloma were affected more
frequently than patients with solid cancers [43] (Table 3).Table 3
Prevalence of ONJ [43].
Type of study Type of bisphosphonate
Overall prevalence 6.1% Zoledronic acid 8.6%
Documented Follow up 13.3% Pamidronate 7.3%
No documented follow up 0.7% Both 21%
Epidemiologic studies 1.2% Oral BP 0.1–4%
Fig. 2. Preventive measures in patients wit3. Preventive and prophylactic measures for patients about to
start and those already established on bone-targeted therapies
In this section we will try and address many of the frequently
asked questions around preventive and prophylactic measures for
patients either starting or already established on bone-targeted
therapy (Figs. 2 and 3). In view of the difﬁculties in treating ONJ,
preventive strategies would seem to make the most sense. The
efﬁcacy of preventive strategies was investigated in two studies.
Authors tried to compare the incidence of ONJ between the
investigational group and a control group. The investigational
group underwent preventive measures including dental assess-
ment prior to bisphosphonate initiation so that any invasive
dental procedures could be completed prior to initiation of
bisphosphonate therapy. Bisphosphonate treatment was delayed
for 6–8 weeks until complete wound healing after surgical
procedures. Whenever possible minor dental interventions with
preservation of dental roots, and avoidance of dento-alveolar
surgery were preferred over tooth extraction and prophylactic
antibiotics were used with invasive procedures. The retrospective
control group of patients had received bisphosphonates before
implementation of preventive measures. Incidence of ONJ was
reduced by two-three times in patients on preventive measures
[44,45]. While this data is not from a randomized trial the authors
did comment that given the effectiveness of ONJ preventive
measures, performing a randomised study with a control group
not receiving these measures would likely be considered
unethical.
According to these studies and numerous recommendations,
patients should be consulted about risk of developing ONJ prior to
initiation of bone-targeted treatments and informed about the
importance of maintaining their oral hygiene. Patients should be
advised to have a dental examination, treatment existing dental
problem and extraction of teeth that cannot be restored, pre-
ferably by a dental surgeon familiar with the risks of ONJ, prior to
starting bisphosphonate therapy. Patients should also avoid
dento-alveolar surgical procedures involving the mandibular or
maxillary bone while actively receiving intravenous bisphospho-
nates, or for several months after completion of the therapy [5].
For patients receiving on-going bone-targeted therapies they too
should continue to have frequent dental examinations. This
allows the identiﬁcation and early treatment of any dentalh bone metastases about to start BTAs.
Fig. 3. Prevention of ONJ in patients on established BTAs.
I. Kuchuk et al. / Journal of Bone Oncology 2 (2013) 38–4642disease, and the establishment of a suitable recall and oral
hygiene program. Maintenance of good oral hygiene is essential
to the prevention of dental disease and is therefore particularly
important for this group of patients. Patients need to be kept
aware of the ongoing risks of ONJ and their association with
surgical dental procedures [46].
A meta-analysis of seven published single centre, non-rando-
mised studies with a prospective interventional cohort and retro-
spective control group investigating the efﬁcacy of preventive
measures was presented recently at cancer-induced bone disease
symposium in Lyon. It showed efﬁcacy of preventive measures
with a relative reduction of 68% of ONJ risk (RR 0.32; 95% CI 0.20–
0.50; po0.001).(Prevention of Osteonecrosis of the Jaw (ONJ) in
Cancer Patients Receiving Bisphosphonates: Empty Promise or
Effective strategy? Tim Van den Wyngaert et al., Antwerp Uni-
versity Hospital, Edegem, Belgium, 12th International Conference
on Cancer-Induced Bone Disease, 15–17 November, 2012, poster
P31, www.nature.com/bonekey)
Given that strategies to avoid ONJ are likely to be more effective
than treating the condition once it occurs, it also seems sensible to
reduce bisphosphonate exposure as much as possible. This can be
accomplished by using less potent agents or less intensive infusion
schedules, particularly in those patients who have been on bone-
targeted agents for protracted periods of time. In multiple myeloma
patients most guidelines recommend stopping bisphosphonates
after two years. Recently emerging data in multiple myeloma
patients suggests that the incidence of ONJ might be lowered by a
reduced dosing schedule without affecting the incidence of skeletal-
related events [47]. The risk of ONJ was eight-fold lower with the
reduced schedule (monthly injection during the ﬁrst year and every
3 months thereafter) than with the standard monthly schedule.
However, this small retrospective study is not conclusive regarding
the efﬁcacy of less frequent dosing or its impact on the development
of ONJ. However, a number of ongoing studies are investigating the
efﬁcacy of less intensive regimens of bisphosphonates in metastatic
bone disease (NCT00320710, NCT00424983). The ZOOM trial, com-
paring a standard 4 weeks versus 12 weeks schedule of zoledronic
acid for the prevention and delay of skeletal related events in
metastatic breast cancer patients was presented at the ASCO meet-
ing 2012 and showed equivalent results for these two regimens [48].4. How do you manage patients on intravenous bone-targeted
agents who require dental work?
For patients who are on IV bisphosphonate therapy and
require dento-alveolar procedures there is a suggestion that
prophylactic antibiotic use around the procedure may be helpful
in reducing ONJ risk [45,49]. A recent study by Lopez-Jornet et al.
showed a statistically signiﬁcant reduction of ONJ with pre and
postoperative antibiotics for extraction procedures in an animal
model [50]. If a surgical procedure is unavoidable, conservative
surgical intervention is preferred in an attempt to minimize
trauma to bone tissue. The procedure should be performed by
experienced clinicians familiar with ONJ, ensuring that a mini-
mally invasive, efﬁcient procedure be performed with minimal
morbidity.5. Should patients on a bone-targeted agent requiring dental
work stop their bone-targeted agent?
Recommendations on need of discontinuation of bisphospho-
nates in patients requiring dental work have not been created yet.
Given the very long half-life of bisphosphonates in bone, with a
12-year terminal half-life even for oral agents like alendronate,
effects of temporary cessation of the agents is questionable
[31,46]. On the other hand, temporary discontinuation of bispho-
sphonates may remove their acute toxic effect on soft tissue and
could facilitate the healing process [5].
AAOMS recommends withholding oral bisphosphonates for up
to 3 months before a surgical procedure and for up to 3 months
thereafter [5]. This strategy also supported by a correlation of the
level of the bone turnover marker, C-terminal telopeptide (CTX)
with risk of development of ONJ. According to Marx et al. morning
fasting serum CTX levels correlated with the duration of oral
bisphosphonate use, with increased values for each month of a
drug holiday when the oral bisphosphonate was discontinued,
suggesting a recovery of bone remodelling during this time.
A rising of CTX was associated with reduced risk of ONJ after
surgical dental procedures [51]. On the other hand, other trials
failed to show a correlation between level of biochemical markers
Fig. 4. Management of established ONJ.
Table 4
Staging of ONJ [3].
Stage Clinical picture
Stage 0 Tooth and jaw pain with no ﬁndings on examination, unexplained
tooth mobility
Stage I Asymptomatic exposed and necrotic bone without infection
Stage II Exposed and necrotic bone with pain and infection
Stage III Exposed and necrotic bone with pain and infection plus
Pathologic fracture or extra-oral ﬁstula/communication or necrosis
I. Kuchuk et al. / Journal of Bone Oncology 2 (2013) 38–46 43(i.e. CTX, N-terminal telopeptide (NTX), or bone speciﬁc alkaline
phosphatase) and risk of development of ONJ [52–54]. It however
must be recognized that inter individual variability, gender, age,
physical activity, and seasonal variation exist that can result in
difﬁculty in interpreting these assays, hence more research is
needed.
There is no conclusive data that stopping of intravenously
given bisphosphonates or denosumab for 2–4-month prior to
dental invasive procedure can reduce the risk of ONJ.extending beyond the region of alveolar bone or oro-antral/oro-nasal
communication6. Management of patients with established osteonecrosis
of the jaw
This section will deal with the care of patients on bone-
targeted agents who then develop ONJ (Fig. 4). Although a
number of clinical guidelines for management of patients with
ONJ have been released by various oncology, oral surgical orga-
nizations and bisphosphonate manufacturers, there is no estab-
lished gold standard, since most recommendations are based on
case-control studies, retrospective analyses and expert opinions.
For patients with established ONJ, treatment objectives are
elimination of pain, control of infection in the soft and bone
tissue, and minimization of the progression or occurrence of bone
necrosis.
In general, patients with ONJ should be evaluated and mana-
ged by a team including an oral and maxillofacial surgeon and an
oncologist [5,46]. Several staging systems of ONJ have been
developed by different dental and oncology organizations to help
facilitate treatment decisions. The most useful system had been
proposed by Ruggiero and subsequently revised by the American
Association of Oral and Maxillofacial Surgeons (Table 4 and Fig. 1).
According to this classiﬁcation, Stage 0 deﬁnes patients present-
ing with non-speciﬁc symptoms such as tooth pain, sinus pain,
and unexplained tooth mobility but without signiﬁcant clinical
ﬁndings on examination. For these patients conservative manage-
ment with topical mouth rinses (chlorhexidine gluconate or
hydrogen peroxide) and analgesia is recommended. This is to
decrease and prevent further progression of infection in the
exposed bone [5,11].Among patients with established infection in the bone or
surrounding tissue (Stage II) antibiotic penicillin-based therapy
in addition to mouthwash may result in healing in patients with
minor ONJ lesions. However, a large proportion of cases tend to
show chronically infected necrotic process in jaw bones with very
limited response to any treatment. Prior to commencement of
antimicrobial (penicillin-based) and antifungal therapy, wound
and pus culture samples, including those for Actinomyces species
should be taken [55,56].
Generally, surgical debridement has been variably effective in
eradicating necrotic bone and is not recommended for early
stages of ONJ due to the concern of possible exacerbation of the
necrotic process [57]. However, in patients with advanced process
(Stage III) with pathological fracture, extra oral ﬁstula, osteolysis
extending to the base of the jaw or recurrent infections, complete
removal of the necrotic bone and where possible immediate
reconstruction in addition to systemic antibiotic treatment is
indicated [58,59].
Several authors reported successful outcome with surgical
treatment of ONJ [9,60,61].
As alternative for conventional conservative surgery, laser
applications at low intensity (low level laser therapy—LLLT) have
been reported in the literature for the treatment of ONJ with
promising results [54,62]. Biostimulatory effects of laser improve
reparative processes, increase inorganic matrix of bone and
stimulate lymphatic and blood capillary growth, as well as having
a bactericidal effect.
I. Kuchuk et al. / Journal of Bone Oncology 2 (2013) 38–4644Hyperbaric oxygenation therapy has shown inconsistent results
and is now under investigation in an ongoing randomised trial as an
addition to surgical or non-surgical treatment [63]. As a result, its
use is not presently recommended outside of clinical trials.
Pentoxifylline (blood viscosity reducer agent) and oral vitamin E
has shown efﬁcacy in a small case series [64].
Ozone (O3) therapy in the management of bone necrosis or in
extractive sites during and after oral surgery in patients treated
with bisphosphonate may stimulate cell proliferation and soft
tissue healing resulting in alleviation of symptoms [6]. However,
several case reports and small uncontrolled studies reported
controversial efﬁcacy of O3 gas formulation in addition to con-
ventional in treatment of ONJ [65,66]
In a phase I and II study, medical O3 has been shown to heal
ONJ if antibiotic therapy (azithromycin) is administered 10 days
prior to O3 oil formulation, where more than half of the patients
showing a complete response with radiologic lesion disappear-
ance following reconstruction of the oral tissue [67].
Teriparatide (synthetic peptide that corresponds to the N-
terminal residues of human parathyroid hormone) therapy has
been recommended to adjust the mechanisms of failed bone
remodelling and have anabolic effects on osteoblasts. Teriparatide
has been shown to help remove necrotic bone for new healthy
bone to be laid down in order to resolve periodontal osseous
defects [68]. Subramanian et al. [69] reported on the off-label use
of teriparatide for ONJ in 6 patients treated with bisphosphonates
for osteoporosis. In this report healing occurred in all cases within
5 months of initiating treatment. In contrast, Narvaez [70]
reported a case of lack of response to teriparatide treatment. Of
note, teriparatide is contraindicated in patients with osteosar-
coma or metastatic bone disease following reports that osteosar-
coma has occurred in rats and people who took the drug [71].
Other treatments such as administration of platelet rich
plasma, and bone morphogenic proteins have been published as
possible procedures in ONJ treatment in small case reports.
Clearly the efﬁcacy of these strategies needs to be established in
additional prospective studies [72].7. Should bisphosphonate therapy be discontinued if
osteonecrosis of the jaw is present?
Decisions about to continue or stop bisphosphonates in face of
established osteonecrosis of the jaw remains controversial.
Although bisphosphonates have not been shown to improve
cancer-speciﬁc survival patients with metastatic bone disease
patients signiﬁcantly beneﬁts from bisphosphonate treatment
through reduced bone pain and a lower incidence of skeletal
related events. Their use is therefore recommended in most
international guidelines, starting once bone metastases are
diagnosed [73–75], however, none give comprehensive recom-
mendations about when to stop treatment.
Recently emerging data suggest that lower frequency of IV
bisphosphonates in metastatic breast cancer has the same efﬁcacy
as monthly regimen [48]. ONJ on the other hand can be extremely
symptomatic with a severely detrimental effect on quality of life.
A case-control study based on risk factors for ONJ conﬁrms
that ONJ is associated with the duration of bisphosphonate
treatment. A higher risk of ONJ began within 2 years of bispho-
sphonate treatment and increased four-fold 2 years later, showing
that even less potent bisphosphonates remain linked to ONJ after
brief treatment therapy [25].
There are several reports that long term discontinuation of IV
bisphosphonates in patients with ONJ may be beneﬁcial in stabilizing
established sites of osteonecrosis and provide improvement ofclinical symptoms [5,46]. However, there have been some cases of
spontaneous resolution during ongoing monthly bisphosphonate
therapy [28,29]. Moreover, Wilde et al. [60] reported favorable
outcome with surgical treatment of ONJ irrespective of whether
bisphosphonates were discontinued or not. In another report, the
patients who developed ONJ after dental procedures safely restarted
bisphosphonate therapy, but those who developed ONJ without a
predisposing cause were at increased risk of recurrence after initial
healing, especially when these agents were reintroduced [76]. Since
bisphosphonates are incorporated into the mineral matrix of bone, it
is unknown as to whether or not stopping bisphosphonate therapy
would be beneﬁcial in managing ONJ [7]. Nevertheless, stopping the
bisphosphonate would remove any acute inﬂuences on the perios-
teum and soft tissues, and could potentially improve the healing
process. [5,31].
Therefore decisions around bisphosphonate withdrawal and
reintroduction after ONJ are complex and should be made using a
multidisciplinary team including oncologist, oral and maxillo-
fascial surgeon and patient and based on weighing the severity of
ONJ symptoms against the beneﬁts from ongoing bisphosphonate
therapy including patients’ overall prognosis and symptoms of
bone metastases [46].8. Discussion
Bone-targeted agents are established standard of care treat-
ments for patients with metastatic bone disease. Generally they
are well tolerated with few side effects, however, in recent years
cases of ONJ have been reported as a rare but serious complica-
tion of treatment. In light of the palliative intent of bispho-
sphonate administration on the one hand and the serious
implications of ONJ on patient’s well-being and quality of life on
the other, it has become an important issue for oncologists,
dentists, and oral and maxillofacial surgeons. Given the increas-
ingly widespread use of highly potent bone-targeted agents such
as bisphosphonates and inhibitors of RANKL function, the pre-
valence of ONJ is likely to continue to increase.
We simply have to accept that while there is growing data on
incidence and risk factors of ONJ, the current data about the
prevention and treatment of ONJ is relatively poor and is based
mainly on case reports, case-controlled series, retrospective
studies and expert opinions. Ongoing prospective trials in meta-
static and adjuvant (D-CARE trial, http://www.clinicaltrials.gov/
ct2/show/NCT01077154) settings with accurate ONJ monitoring
will help us answer many more questions about the prevention
and management of this condition. In particular strategy looking
at de-escalating regimens in patients with bone metastases that
can reduce exposure of the jaw to bisphosphonates and therefore
reduced risk of ONJ and improve patient care [48].
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